DE60202296D1 - Pharmazeutische verbindungen mit serotonin rezeptor aktivität - Google Patents

Pharmazeutische verbindungen mit serotonin rezeptor aktivität

Info

Publication number
DE60202296D1
DE60202296D1 DE60202296T DE60202296T DE60202296D1 DE 60202296 D1 DE60202296 D1 DE 60202296D1 DE 60202296 T DE60202296 T DE 60202296T DE 60202296 T DE60202296 T DE 60202296T DE 60202296 D1 DE60202296 D1 DE 60202296D1
Authority
DE
Germany
Prior art keywords
receptor activity
pharmaceutical compounds
serotonin receptor
serotonin
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60202296T
Other languages
English (en)
Inventor
Jeremy Gilmore
Carlos Lamas-Peteira
Varela Alicia Torrado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from PCT/US2002/016594 external-priority patent/WO2003006455A1/en
Application granted granted Critical
Publication of DE60202296D1 publication Critical patent/DE60202296D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60202296T 2001-07-11 2002-06-27 Pharmazeutische verbindungen mit serotonin rezeptor aktivität Expired - Lifetime DE60202296D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36161101P 2001-07-11 2001-07-11
EP01500181 2001-07-11
PCT/US2002/016594 WO2003006455A1 (en) 2001-07-11 2002-06-27 Pharmaceutical compounds with serotonin receptor activity

Publications (1)

Publication Number Publication Date
DE60202296D1 true DE60202296D1 (de) 2005-01-20

Family

ID=26077297

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60202296T Expired - Lifetime DE60202296D1 (de) 2001-07-11 2002-06-27 Pharmazeutische verbindungen mit serotonin rezeptor aktivität

Country Status (2)

Country Link
US (1) US20040180883A1 (de)
DE (1) DE60202296D1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855471B1 (ko) * 2009-12-04 2018-05-09 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
SG11201900687VA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
US6162803A (en) * 1998-04-08 2000-12-19 American Home Products Corp. Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression

Also Published As

Publication number Publication date
US20040180883A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE359064T1 (de) Pharmazeutische tramadolsalze
ATE458486T1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
ATE460169T1 (de) Pharmazeutische formulierung mit lanthanum- verbindungen
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
NO20053150D0 (no) System for administrasjon av medisin.
DE60014279D1 (de) Stiftförmige Medikamentenspritze
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
NO20030627L (no) Hydrogel-drevet medikament doseringsform
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
IT1311921B1 (it) Composti farmaceutici.
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60202296D1 (de) Pharmazeutische verbindungen mit serotonin rezeptor aktivität
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE412405T1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger

Legal Events

Date Code Title Description
8332 No legal effect for de